U.S. Markets open in 4 hrs 39 mins
  • S&P Futures

    3,944.00
    +46.25 (+1.19%)
     
  • Dow Futures

    31,497.00
    +295.00 (+0.95%)
     
  • Nasdaq Futures

    12,078.75
    +200.50 (+1.69%)
     
  • Russell 2000 Futures

    1,800.30
    +25.40 (+1.43%)
     
  • Crude Oil

    111.65
    -0.56 (-0.50%)
     
  • Gold

    1,843.80
    +2.60 (+0.14%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0580
    -0.0008 (-0.0741%)
     
  • 10-Yr Bond

    2.8550
    0.0000 (0.00%)
     
  • Vix

    28.51
    -2.45 (-7.91%)
     
  • GBP/USD

    1.2480
    +0.0006 (+0.0462%)
     
  • USD/JPY

    128.0090
    +0.2150 (+0.1682%)
     
  • BTC-USD

    30,258.79
    +1,159.63 (+3.99%)
     
  • CMC Crypto 200

    674.24
    +22.01 (+3.37%)
     
  • FTSE 100

    7,416.05
    +113.31 (+1.55%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Rigel's Fostamatinib Selected for NIH ACTIV-4 COVID-19 Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Rigel Pharmaceuticals Inc's (NASDAQ: RIGL) fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 trial in hospitalized patients with COVID-19.

  • Fostamatinib will be the fourth arm of our ACTIV-4 Host Tissue trial that aims to protect and heal host tissues in hospitalized patients with COVID-19.

  • This study follows a recently completed NHLBI/NIH-sponsored Phase 2 study in COVID-19.

  • The study met its primary endpoint of safety. It showed broad and consistent improvement in numerous efficacy endpoints, including mortality, ordinal scale assessment, and the number of days in the ICU.

  • These data were submitted as part of an emergency use authorization request from the FDA for fostamatinib in hospitalized patients diagnosed with COVID-19.

  • Price Action: RIGL shares are down 0.11% at $4.47 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.